RESUMEN
Seizure frequency in treatment-resistant epilepsies seems to be decreased by cannabidiol (CBD), but contrasting data are available on its effect on sleep, behavior, and quality of life (QoL), and no data is reported on its effect on parental stress in patients with epilepsy (PWE). Thus, we conducted a retrospective study on a cohort of children and adults with drug-resistant epilepsy (DRE) who had been treated with highly purified, pharmaceutical-grade CBD to evaluate its effects on seizure frequency, QoL, behavior, parental stress, and sleep. Eighteen patients (12 adults and 6 children) were included in the cohort and followed for a median of 9 months. At the last follow-up (Tn), nine patients (50%) were considered CBD responders with at least a 50% decrease in seizure frequency. No serious adverse effects were found. No statistically significant differences were found concerning sleep, including daytime sleepiness, and no statistically significant effect was found on parental stress at Tn. An improvement was found for social interaction in quality of life (p < 0.05) for all patients. Our results demonstrate that CBD is a safe and effective antiseizure medication (ASM). CBD doesn't seem to affect sleep measures in adults and children or worsen daytime sleepiness. However, CBD improves specific QoL measures, which could indicate a possible use of CBD for other childhood disabilities. No impact of CBD was seen on parental stress, which could possibly be due to the limited follow-up or could mean that parental stress is not dependent on seizure frequency.
Asunto(s)
Cannabidiol , Trastornos de Somnolencia Excesiva , Epilepsia Refractaria , Epilepsia , Niño , Adulto , Humanos , Cannabidiol/uso terapéutico , Anticonvulsivantes/uso terapéutico , Calidad de Vida , Estudios Retrospectivos , Convulsiones/tratamiento farmacológico , Convulsiones/inducido químicamente , Epilepsia Refractaria/tratamiento farmacológico , Epilepsia Refractaria/inducido químicamente , Epilepsia/tratamiento farmacológico , Sueño , Trastornos de Somnolencia Excesiva/inducido químicamenteRESUMEN
Epilepsy surgery is recommended in selected patients with Tuberous Sclerosis Complex (TSC). However, reports on predictive factors of seizure outcome are variable. Here we report on seizure and cognitive outcome of 35 TSC patients who received surgery for refractory epilepsy in 7 Italian centers over a period of 22 years (1997-2019). The rate of seizure-free individuals at last follow-up (mean 7.5 years, range 1-21 years) was 51%. Patients with longer follow-up (≥10 years) had a lower rate of Engel I outcome (11.1%) than those who received surgery in the last 10 years (65.4%, p = 0.003). Factors associated with Engel II, III, IV outcome in our cohort included: high number of cortical tubers (≥5); presence of subependymal nodules (SENs); seizure onset before age 1 year; and multifocal interictal epileptic discharges (IEDs) on electroencephalogram (EEG). A subset of patients evaluated with Vineland Adaptive Behaviour Scales (VABS) showed developmental gains, in line with their developmental trajectories, but no improvement in standard scores after surgery was noted. Our study demonstrates that the rates of successful seizure outcome of epilepsy surgery in TSC have improved in the last 10 years. More than half of the patients achieved seizure freedom, and a high proportion of affected individuals experienced a reduction in seizure burden and in antiseizure medications. A comprehensive assessment after surgery should be performed in TSC patients to evaluate the overall neurodevelopmental outcome, as measures that are based only on seizure control do not adequately identify the benefits of surgery on global functioning in these patients.
Asunto(s)
Epilepsia , Esclerosis Tuberosa , Electroencefalografía , Epilepsia/etiología , Epilepsia/cirugía , Humanos , Lactante , Estudios Retrospectivos , Convulsiones/epidemiología , Convulsiones/etiología , Convulsiones/cirugía , Resultado del Tratamiento , Esclerosis Tuberosa/complicaciones , Esclerosis Tuberosa/cirugíaRESUMEN
BACKGROUND: Seizures in individuals affected by tuberous sclerosis complex (TSC) commonly develop in the first year of life, are often preceded by a progressive deterioration of the electroencephalogram (EEG), and likely influence developmental outcome. Although early diagnosis of TSC has offered a tremendous opportunity to monitor affected patients before seizure onset, reports of the neurological manifestations of TSC in infants before seizure onset are still scarce. Here we describe early EEG activity, clinical and genetic data and developmental assessment in a group of TSC infants, with the aim of identifying possible prognostic factors for neurodevelopmental outcome. METHODS: We report on six infants diagnosed with TSC pre- or perinatally, who underwent serial Video-EEG recordings during the first two years of life. EEGs were classified based on distribution and intensity of interictal epileptiform discharges, and Vigabatrin was introduced in case of ictal discharges. Psychomotor development, cognitive functioning and behavioral problems were assessed through standardized scales. Molecular testing included analysis for point mutations and deletions/duplications in TSC1 and TSC2. RESULTS: EEG abnormalities appeared at a mean age of 4 months. Four of the six patients developed seizures. EEG abnormalities preceded the onset of clinical seizures in all of them. The two individuals with good seizure control showed normal development, while the other two exhibited psychomotor delays. The patients who did not develop seizures had normal development. A pathogenic variant in the TSC2 gene was detected in all patients but one. The one without a mutation identified did not develop seizures and showed normal neurodevelopment. Of note, the two patients presenting with the worst outcome (that is, poor seizure control and intellectual/behavioral disability) both carried pathogenic variants in the GAP domain of TSC2. CONCLUSION: Our report supports the importance of EEG monitoring before seizure onset in patients with TSC, and the correlation between prompt seizure control and positive neurodevelopmental outcome, regardless of seizure type. Our results also indicate a possible role of the genetic background in influencing the outcome.
Asunto(s)
Trastornos del Neurodesarrollo/etiología , Convulsiones/etiología , Proteína 1 del Complejo de la Esclerosis Tuberosa/genética , Proteína 2 del Complejo de la Esclerosis Tuberosa/genética , Esclerosis Tuberosa/diagnóstico , Esclerosis Tuberosa/genética , Preescolar , Diagnóstico Precoz , Electroencefalografía , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Mutación/genética , Trastornos del Neurodesarrollo/diagnóstico , Estudios Retrospectivos , Convulsiones/diagnóstico , Esclerosis Tuberosa/complicacionesRESUMEN
AIM: The aim of this study was to investigate the presence of learning disorders in children with idiopathic epilepsy. METHODS: The study enrolled 16 children with idiopathic epilepsy, 8 with absence and 8 with rolandic epilepsy. This was a standardized neuropsychological assessment with particular attention to learning performance (reading and writing skills/number processing). RESULTS: Fourteen out of 16 subjects resulted with a specific learning disability, although specific patterns have not been identified. CONCLUSION: The study confirms the higher incidence of learning disorder in children with epilepsy (in front of normal prevalence, 2-10%). The importance of complete neuropsychological evaluation in children with focal or generalized epilepsy was highlighted.